LUNAC Therapeutics shortlisted for two key industry awards
Leeds, UK, 21 January 2021: LUNAC Therapeutics (LUNAC), a UK based drug discovery company focused on the development of advanced life-saving anticoagulants, announces that it has been shortlisted for two prestigious industry awards.
LUNAC is nominated for the Bionow ‘Start Up of the Year Award’ and is also in contention for the ‘Best Biotech Start-up’ at the OBN Awards.
The 19th Bionow Awards will take place with an online ceremony on Thursday 4 February 2021, showcasing the best of this world class sector.
The Start-Up Award recognises organisations that are using innovative approaches to solve a significant healthcare need, and where the company has a high-growth potential.
Bionow is a not-for-profit membership organisation supporting the biomedical, pharma and life sciences sectors across the North of England. The awards bring together leaders in the North of England’s life sciences industry and recognises life sciences companies, academics and health organisations for their application of cutting-edge technologies. More information about the event can be found here: https://bionow.co.uk/2020-bionow-awards-competition
The Best Biotech Award is given to early-stage companies demonstrating exciting approaches to solve unmet clinical need and the potential to show real-world patient benefit.
OBN is a not-for-profit membership organisation supporting innovative life sciences companies, corporate partners and investors. The OBN Awards celebrate outstanding achievement throughout the life sciences industry and looks to showcase companies at all stages of development, recognising inspirational leadership, exciting innovation, novel and exciting approaches to unmet clinical need, outstanding company progression and the delivery of real-life tangible results.
The OBN awards will take place at the Royal Lancaster in London on Friday 11 June 2021. More information about the event can be found here: https://obn-awards.com
Carl Sterritt, Chief Executive Officer, LUNAC Therapeutics Limited, said:
“We are delighted that LUNAC has been shortlisted for these two prestigious accolades. Together with the recent publication in PNAS of one of our founders, Prof Philippou’s, latest academic research into the likely benefits of targeting Factor XII versus current targets in the coagulation cascade, these nominations clearly illustrate the considerable potential of LUNAC’s technology. Together with our investors, we believe the products LUNAC develops from this ground-breaking academic research will create a paradigm shift in the treatment of clot prevention and in doing so, transform patients’ lives with innovative, first-in-class, next generation oral anticoagulants by delivering much-needed therapeutic benefits without the bleeding risk associated with current anticoagulants.”